Natco Pharma gets nod to invest up to Rs 1,400 crore in NPSAPL

Natco Pharma has secured approval to make an investment of up to Rs 1,400 crore in Natco Pharma South Africa Proprietary (NPSAPL), wholly owned subsidiary of the company. The Board of Directors of the company at its meeting held on July 08, 2026, has approved the same. The objective of the investment is to enter new geographies for growth and increased profitability. The investment is expected to be completed before the end of July of 2026. NPSAPL is incorporated in South Africa for the purposes of having presence in the continent of Africa. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).